伏诺拉生联合艾司奥美拉唑对Hp阳性难治性胃食管反流病患者的效果OA
The Effect of Vonoprazan Combined with Esomeprazole on the Level of Gastrointestinal Hormones and Therapeutic Efficacy in Patients with Hp-Positive Refractory Acid Reflux Disease
目的:探究临床对于幽门螺旋杆菌(Hp)阳性难治性胃食管反流病患者采用伏诺拉生、艾司奥美拉唑联合用药的临床效果.方法:选取 2021 年 1 月—2023 年 10 月东台市人民医院收治的 80 例Hp阳性难治性胃食管反流病患者作为研究对象,按照治疗差异性分为对照组和研究组,每组各 40 例.两组均采取基础干预,对照组予以艾司奥美拉唑治疗,研究组在对照组基础上联合富马酸伏诺拉生片药物治疗.比较两组胃肠激素水平、炎症因子、不良反应情况及临床疗效.结果:治疗前,两组胃肠激素水平比较,差异无统计学意义(P>0.05);治疗后,研究组血管活性肠肽较治疗前降低,且低于对照组,差异有统计学意义(P<0.05);治疗后,研究组胃泌素、胃动素均较治疗前升高,且高于对照组,差异有统计学意义(P<0.05).治疗前,两组炎症因子水平比较,差异无统计学意义(P>0.05);治疗后,研究组C反应蛋白、白细胞介素-6、肿瘤因子-α均较治疗前降低,且低于对照组,差异有统计学意义(P<0.05).治疗后,研究组腹痛、腹泻、恶心呕吐反应发生率低于对照组,差异有统计学意义(P<0.05).治疗后,研究组总有效率高于对照组,差异有统计学意义(P<0.05).结论:采用伏诺拉生联合艾司奥美拉唑用药后可Hp阳性难治性胃食管反流病患者中的胃肠激素及炎症因子水平,从而对改善患者的临床效果且联合用药的安全性较高.
Objective:To investigate the clinical effect of combined administration of voronolazone and esomeprazole in patients with refractory gastroesophageal reflux(GERD)positive helicobacter pylori(Hp).Method:A total of 80 patients with Hp-positive refractory GERD treated in Dongtai People's Hospital from January 2021 to October 2023 were selected as the study objects,and grouped according to treatment differences,with 40 cases in each group.Patients in both groups received basic intervention.The control group was treated with esomeprazole,while the study group was treated with Vonolazine fumarate tables on the basis of control group.The levels of gastrointestinal hormones,inflammatory factors,adverse reactions and clinical efficacy of the two groups were compared.Result:Before treatment,there was no significant difference in gastrointestinal hormone levels between the two groups(P>0.05).After treatment,VIP in the study group was lower than that before treatment,and lower than that in control group,with statistically significance(P>0.05).After treatment,gastrin and motilin in study group were higher than that before treatment,with statistical significance(P<0.05).Before treatment,there was no significant difference in the levels of inflammatory factors between the two groups(P>0.05).After treatment,CRP,C-creative protein,interleukin-6 and TNF-α in the study group were lower than those before treatment and lower than those in control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of abdominal pain,diarrhea,nausea and vomiting in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:Venolazan combined with esomeprazole can improve the level of gastrointestinal hormones and inflammatory factors in patients with Hp-positive refractory gastroesophageal reflux disease,thus improving the clinical effect of patients with high safety.
梅策淇;崔良臣
东台市人民医院 江苏 东台 224200
伏诺拉生艾司奥美拉唑Hp阳性难治性胃食管反流病疗效胃肠激素水平
VnorazanEsomeprazoleHp-positive refractory gastroesophageal reflux diseaseCurative effectGastrointestinal hormone levels
《中外医学研究》 2024 (036)
21-24 / 4
评论